Market Newsdesk

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) — IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced an upcoming presentation that provides an update of the ongoing Phase I clinical trial of their product candidate INB-100 at the 62nd American Society of Hematology Annual Meeting & Exposition (“ASH”), which will take place virtually from December 5 to 8, 2020. INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.

The poster and accompanying narrated slide presentation is titled, “First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated gamma delta T-Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide” and reviews the study design and provides a brief update on enrollment and patient status.

The company reported that, as of abstract submission, three female subjects with acute leukemia had been enrolled in the INB-100 Phase 1 trial, of whom two had been dosed, and that no treatment-related adverse events had been recorded. The trial is continuing to enroll and treat patients. The abstract for the presentation can be found at https://ash.confex.com/ash/2020/webprogram/Paper142876.html.

The poster and slide presentation are jointly authored by the scientific and physician investigators from IN8bio and The University of Kansas Cancer Center (KU Cancer Center), and will be presented by the study’s Principal Investigator, Dr. Joseph McGuirk, Schutte-Speas Professor of Hematology-Oncology, Division Director of Hematological Malignancies and Cellular Therapeutics and Medical Director, Blood and Marrow Transplant at KU Cancer Center.

“This preliminary data report from KU Cancer Center with our allogeneic product candidate, INB-100, demonstrates the absence of significant GvHD in these initial patients,” said William Ho, Chief Executive Officer of IN8bio. “This suggests that gamma delta T-cells delivered as an off-the-shelf allogeneic cell therapy may be well tolerated and have significant potential to treat patients with serious and life-threatening cancers.”

Dr. McGuirk, commented, “Potentially curative stem cell transplants using partially matched donors — called haploidentical transplants – have greatly expanded access to stem cell transplantation. The infusion of donor-derived gamma delta T-cells from the stem cell donor, offers the hope of diminishing this risk of relapse and curing more patients.”

About IN8bio

IN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio’s technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit www.IN8bio.com.

Forward Looking Statements

Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding the curative potential of its product candidates, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:

IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.933.5605
[email protected]

Investor Contact:

Julia Balanova
+ 1 646.378.2936
[email protected]

Media Contact:

Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, Inc.
212-213-0006 ext. 315 / 364
[email protected] / [email protected]

Auckland, New Zealand, Dec. 03, 2020 (GLOBE NEWSWIRE) — (via Blockchain Wire)  Software development firm Sylo has officially launched Oya, a complete reimagining of their backend architecture that leads the way for mainstream decentralisation.

Centering around the release of user-run nodes, the technology released in the Oya launch is the final pivotal stage of the long-held Sylo vision to democratize access to communication and financial capabilities, without sacrificing privacy, personal data and user experience.

Through Oya, Sylo transforms its over a quarter of a million users into empowered participants able to easily take part by either strengthening the Sylo Network through their usage, or by extending the power and reach of the network by running a Sylo Node. Special attention has been given to transform these technical concepts into simple realities, and everyday users will be able to participate in these previously complex technologies by means of straightforward UI in their Sylo Smart Wallet.

Benefits to Sylo users include the provision of fast, consistently reliable, and fully decentralised communication and financial capabilities, through privacy-preserving apps such as the Sylo Smart Wallet, as well as the ability to run and own a Sylo Node, providing communication and storage services on the Sylo Network and to receive rewards for their contributions. In time, the reward system will shift towards the full incentivization model as outlined in the Sylo Incentivisation whitepaper.

For decentralised apps, the launch of Oya results in the ability to run without a single point of control, all whilst scaling at rates of experience quality never before possible. Overall, the outcome of Oya is a powerful user-run network that can scale to support millions of users, transactions, apps, and businesses.

Further extending into the ability to provide world citizens with access to freedom of choice, additional benefits of the Oya launch functionality include the ability to create micro-networks. These can be simply created by a group of friends all utilising one person’s Sylo Node, resulting in a mini ‘mesh’ style network that does not even require the support of the Sylo Network to provide communication.

After nearly a year of concentrated work from the Sylo backend development team, the Oya launch solves many of the previously unworkable issues experienced by decentralised technologies, propelling decentralisation forward to a real-world, viable solution for Sylo users everywhere. It also sets a solid base for exciting functionalities such as stake and yield opportunities, like Sylo Social DeFi, which will be released to the Sylo Smart Wallet in the coming months.

“We consider the Oya Launch the beginning of mainstream decentralisation,” says Ben Jordan, Sylo Co-Founder and Product Director. “We’ve solved the hard issues of scalability, performance, and fair-reward in a decentralised setting, allowing developers to build apps with a real competitive advantage. The launch of Oya brings our vision of a future worth looking forward to, a whole lot closer and we’re really excited about what can be built on this new decentralised foundation.”

“The Oya Launch opens the door to a plethora of new features and business opportunities, many of which we will be unveiling over the next two quarters,” says Dorian Johannink, Sylo Co-Founder and Business Director. 

ENDS

ABOUT SYLO

Sylo is an international software development house founded in 2010. Committed to decentralisation, they are the core developers of the Sylo Network, the Sylo Protocol and the Sylo Smart Wallet. A next-gen app, the Sylo Smart Wallet sleekly combines a digital asset wallet with a decentralised private messenger. The app allows users to request and receive payments in chat, store and interact with digital assets such as BTC or any ERC-20 compatible token like SYLO, in a non-custodial wallet, utilise a Web3 Ethereum dApp browser, and pay using cryptocurrency in the real world.
For further announcements, follow Sylo on Twitter, Medium or visit www.sylo.io. 

Download the Sylo Smart Wallet from the Google Play or Apple App stores.

Download supporting imagery here.

Media contacts:

Anabela Rea
Content & Public Relations Manager
Sylo
[email protected]

Susan Joseph
Lumos Labs
[email protected]

BRYN MAWR, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) — The weekly magazine, Newsweek, has announced their America’s Best Banks list for 2021. Bryn Mawr Trust (BMT), wholly owned by Bryn Mawr Bank Corporation (NASDAQ: BMTC), has been named America’s Best Bank in Pennsylvania, for the Small Bank division.

According to the Newsweek website, BMT was selected from an initial group of more than 2,500 FDIC-insured financial institutions, and assessed based on 55 different factors. Among the factors considered were “a wide variety of fees, current and historical interest rates, account terms, consumer service features, mobile app satisfaction, and bank profile,” according to Newsweek’s ranking methodology.

BMT has made significant upgrades to its online banking platforms in the last few years – including regular enhancements of its BMT Mobile Banking applications designed for consumers, small businesses, and commercial banking clients. In 2019/2020, the online account opening experience enhancements included a more intuitive client interface for business and personal deposit and loan products and streamlined back-office processes.

Frank Leto, president and chief executive officer of Bryn Mawr Bank Corporation, referenced the Corporation’s long-term strategic planning and investments in human capital and technology. “The recognition is wonderful and validates our efforts,” said Leto. “We have been relentless in our pursuit of efficiency, self-service technologies that consumers and business demand, and a strong value proposition within our product lines. We are particularly pleased that Newsweek considered the quality of our mobile app. Our customers’ digital experience has been a major focus for us in recent years.”

Kevin Tylus, BMT banking division president, also extolled the quality of the Bank’s employees. “This recognition speaks volumes about the collective effort of everyone who works at BMT,” said Tylus. “We were in a position to win this award because of the employees who design and deliver the quality, competitive solutions that our customers rely on.”

Newsweek offered their ideal profile for a Best Small Bank category winner: “A hometown bank that offers the personalized feel of local branch service, while delivering competitive rates, and mobile banking performance on par with larger national banks which can be a great choice for many customers. Add in low fees and a variety of financial products, including loans, and you have a small-bank winner.”

Bryn Mawr Bank Corporation (NASDAQ: BMTC), including its principal subsidiary, The Bryn Mawr Trust Company (BMT), was founded in 1889, and is headquartered in Bryn Mawr, Pa. BMT is a locally managed, premier financial services company providing retail and commercial banking; trust administration and wealth management; and insurance and risk management solutions. Bryn Mawr Bank Corporation has $5.05 billion in corporate assets and $17.24 billion in wealth assets under management, administration, supervision, and brokerage (as of 9/30/20). Today, the company operates 41 banking locations, seven (7) wealth management offices and two (2) insurance and risk management locations in the following counties: Montgomery, Chester, Delaware, Philadelphia, and Dauphin Counties in Pennsylvania; New Castle County in Delaware; and Mercer and Camden Counties in New Jersey. For more information, visit bmt.com.

FORWARD-LOOKING STATEMENTS AND SAFE HARBOR

This communication contains statements which, to the extent that they are not recitations of historical fact may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Such forward-looking statements may include financial and other projections as well as statements regarding the Corporation’s future plans, objectives, performance, revenues, growth, profits, operating expenses or the Corporation’s underlying assumptions. The words “may,” “would,” “should,” “could,” “will,” “likely,” “possibly,” “expect,” “anticipate,” “intend,” “indicate,” “estimate,” “target,” “potentially,” “promising,” “probably,” “outlook,” “predict,” “contemplate,” “continue,” “plan,” “strategy,” “forecast,” “project,” “annualized,” “are optimistic,” “are looking,” “are looking forward” and “believe” or other similar words and phrases may identify forward-looking statements. Persons reading this communication are cautioned that such statements are only predictions, and that the Corporation’s actual future results or performance may be materially different.

Such forward-looking statements involve known and unknown risks and uncertainties. A number of factors, many of which are beyond the Corporation’s control, could cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed, implied or anticipated by such forward-looking statements, and so our business and financial condition and results of operations could be materially and adversely affected. The COVID-19 pandemic (the “Pandemic”) is adversely affecting us, our clients, counterparties, employees, and third-party service providers, and the ultimate extent of the impacts on our business, financial position, results of operations, liquidity, and prospects is uncertain. Continued deterioration in general business and economic conditions, including further increases in unemployment rates, or turbulence in domestic or global financial markets could adversely affect our revenues and the values of our assets and liabilities, reduce the availability of funding, lead to a tightening of credit, and further increase stock price volatility. In addition, changes to statutes, regulations, or regulatory policies or practices as a result of, or in response to the Pandemic, could affect us in substantial and unpredictable ways. Other factors include, among others, our need for capital, our ability to control operating costs and expenses, and to manage loan and lease delinquency rates; the credit risks of lending activities and overall quality of the composition of our loan, lease and securities portfolio; the impact of economic conditions, consumer and business spending habits, and real estate market conditions on our business and in our market area; changes in the levels of general interest rates, deposit interest rates, or net interest margin and funding sources; changes in banking regulations and policies and the possibility that any banking agency approvals we might require for certain activities will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to implement our business plans; changes in accounting policies and practices or accounting standards, including ASU 2016-13 (Topic 326), “Measurement of Credit Losses on Financial Instruments,” commonly referenced as the Current Expected Credit Loss model, which has changed how we estimate credit losses and may result in further increases in the required level of our allowance for credit losses; unanticipated regulatory or legal proceedings, outcomes of litigation or other contingencies; cybersecurity events; the inability of key third-party providers to perform their obligations to us; our ability to attract and retain key personnel; competition in our marketplace; war or terrorist activities; material differences in the actual financial results, cost savings and revenue enhancements associated with our acquisitions; uncertainty regarding the future of LIBOR; the impact of public health issues and pandemics, and their effects on the economic and business environments in which we operate, the effect of the Pandemic, including on our credit quality and business operations, as well as its impact on general economic and financial market conditions; and other factors as described in our securities filings with the U.S. Securities and Exchange Commission (“SEC”). All forward-looking statements and information set forth herein are based on Corporation management’s current beliefs and assumptions as of the date hereof and speak only as of the date they are made. The Corporation does not undertake to update forward-looking statements.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with the SEC, including our most recent Annual Report on Form 10-K, as updated by our quarterly or other reports subsequently filed with the SEC, including our most recent Quarterly Report on Form 10-Q.